Development of Dual-Receptor Lysosome-Targeting Chimeras for Protein Degradation

A growing array of lysosome-targeting chimeras (LYTACs) have recently emerged as therapeutic candidates to treat malignancies and other diseases via targeted protein degradation. We established a novel dual lysosome-targeting receptor-dependent protein degradation strategy that leverages the synergistic actions of the C-X-C chemokine receptor 4 (CXCR4) and folate receptor 1 (FOLR1) to degrade extracellular and membrane proteins. Using this strategy, we developed dual-receptor lysosome-targeting chimeras to achieve efficient lysosomal degradation of programmed cell death ligand 1 (PD-L1) and epidermal growth factor receptor (EGFR). The EGFR chimera inhibited the growth of transplanted T790M-mutated drug-resistant EGFR-driven lung cancer tumors by degrading EGFR. This dual-targeting strategy exhibits significantly better protein degradation capabilities compared with single lysosome-targeting chimeras, providing a novel platform for developing drugs targeting cancer.

Authors

Institutions

Publication Details

Journal
Journal of the American Chemical Society
Published
2025-10-23
DOI
https://doi.org/10.1021/jacs.5c13695
Citations
3
Primary Topic
Protein Degradation and Inhibitors
Type
article
Field-Weighted Citation Impact
2.42
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Development of Dual-Receptor Lysosome-Targeting Chimeras for Protein Degradation

Hailong Zhang, Chen Gong, Xuegong Fan, Xudong Sun et al.
3 citations
Journal of the American Chemical Society
Protein Degradation and Inhibitors
2.42
article

Development of Dual-Receptor Lysosome-Targeting Chimeras for Protein Degradation

Hailong Zhang, Chen Gong, Xuegong Fan, Xudong Sun, Guoxiong Zhou, Kun Wang, Rui Wang, Ke Wang, Hange Yang, Juan Yi, Peihong Ji, Kuan Hu, Cong Wang
article en
3 citations

Abstract

A growing array of lysosome-targeting chimeras (LYTACs) have recently emerged as therapeutic candidates to treat malignancies and other diseases via targeted protein degradation. We established a novel dual lysosome-targeting receptor-dependent protein degradation strategy that leverages the synergistic actions of the C-X-C chemokine receptor 4 (CXCR4) and folate receptor 1 (FOLR1) to degrade extracellular and membrane proteins. Using this strategy, we developed dual-receptor lysosome-targeting chimeras to achieve efficient lysosomal degradation of programmed cell death ligand 1 (PD-L1) and epidermal growth factor receptor (EGFR). The EGFR chimera inhibited the growth of transplanted T790M-mutated drug-resistant EGFR-driven lung cancer tumors by degrading EGFR. This dual-targeting strategy exhibits significantly better protein degradation capabilities compared with single lysosome-targeting chimeras, providing a novel platform for developing drugs targeting cancer.

Journal of the American Chemical SocietyVol. 147(44)
Academy of Medical Sciences (GB), Chinese Academy of Medical Sciences & Peking Union Medical College (CN), Peking Union Medical College Hospital (CN), Gansu University of Traditional Chinese Medicine (CN), Shanghai Institute of Materia Medica (CN), Lanzhou University (CN)
Openalex Percentile: Top 10%
Protein Degradation and Inhibitors
2.42
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.